Guenther Koehne

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Cancer-testis antigen expression and immunogenicity in AL amyloidosis
    M A Rosenzweig
    Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Cancer Center, Duarte, CA, USA
    Blood Cancer J 2:e90. 2012
  2. doi Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care
    Guenther Koehne
    Adult Bone Marrow Transplantation Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Curr Opin Oncol 24:720-6. 2012
  3. ncbi Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors
    Guenther Koehne
    Department of Pediatrics, Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 99:1730-40. 2002
  4. ncbi [131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity
    Pat Zanzonico
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Eur J Nucl Med Mol Imaging 33:988-97. 2006
  5. pmc A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation
    Doris M Ponce
    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Biol Blood Marrow Transplant 19:799-803. 2013
  6. ncbi Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants
    RICHARD J O'REILLY
    Department of Pediatrics, Memorial Sloan Kettering Cancer Institute, New York, NY, USA
    Immunol Res 38:237-50. 2007
  7. pmc T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease
    Jenna D Goldberg
    Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Biol Blood Marrow Transplant 19:208-13. 2013
  8. pmc Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation
    Doris M Ponce
    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Biol Blood Marrow Transplant 17:1316-26. 2011
  9. pmc Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant
    Jenna D Goldberg
    Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma 53:1124-9. 2012
  10. doi A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients
    Craig S Sauter
    Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Department of Medicine, Weill Cornell Medical College, New York, New York Electronic address
    Biol Blood Marrow Transplant 20:354-60. 2014

Collaborators

Detail Information

Publications24

  1. pmc Cancer-testis antigen expression and immunogenicity in AL amyloidosis
    M A Rosenzweig
    Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Cancer Center, Duarte, CA, USA
    Blood Cancer J 2:e90. 2012
    ..This study identifies CT7 as the prevalent CTA in plasma cells of patients with AL amyloidosis. Further analyses determining the biology of CTAs in AL amyloidosis and their value as potential targets for immunotherapy are warranted...
  2. doi Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care
    Guenther Koehne
    Adult Bone Marrow Transplantation Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Curr Opin Oncol 24:720-6. 2012
    ..In this review, we summarize the emerging data on allo HSCT and provide suggestions for its optimal role in the treatment of myeloma...
  3. ncbi Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors
    Guenther Koehne
    Department of Pediatrics, Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 99:1730-40. 2002
    ..Strikingly, the CD4(+)IFN-gamma(+) cell fractions were not cytotoxic against EBV-transformed or allogeneic targets...
  4. ncbi [131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity
    Pat Zanzonico
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Eur J Nucl Med Mol Imaging 33:988-97. 2006
    ....
  5. pmc A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation
    Doris M Ponce
    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Biol Blood Marrow Transplant 19:799-803. 2013
    ..It also represents a promising alternative to high-dose conditioning in younger patients...
  6. ncbi Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants
    RICHARD J O'REILLY
    Department of Pediatrics, Memorial Sloan Kettering Cancer Institute, New York, NY, USA
    Immunol Res 38:237-50. 2007
    ..New more predictable strategies are under development, which should allow such therapies to be broadly applicable...
  7. pmc T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease
    Jenna D Goldberg
    Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Biol Blood Marrow Transplant 19:208-13. 2013
    ..15 (95% CI, 0.04-0.26), and that of extensive chronic GVHD at 2 and 5 years was 0.05 (95% CI, 0-11.6). We demonstrate OS and DFS rates that compare favorably to unmodified allo-HSCT with lower rates of GVHD...
  8. pmc Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation
    Doris M Ponce
    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Biol Blood Marrow Transplant 17:1316-26. 2011
    ..482). These data provide strong support for the further investigation of double-unit CB grafts as an alternative hematopoietic stem cell source...
  9. pmc Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant
    Jenna D Goldberg
    Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma 53:1124-9. 2012
    ..These data demonstrate that allogeneic transplant is a viable option for the treatment of T-NHL and merits prospective evaluation...
  10. doi A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients
    Craig S Sauter
    Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Department of Medicine, Weill Cornell Medical College, New York, New York Electronic address
    Biol Blood Marrow Transplant 20:354-60. 2014
    ..001). This nonmyeloablative regimen, with peritransplant rituximab, is safe and effective in patients with B-NHL...
  11. pmc Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation
    Ekaterina Doubrovina
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 119:2644-56. 2012
    ....
  12. pmc Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes
    Juliet N Barker
    Department of Medicine, Allogeneic Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 116:5045-9. 2010
    ..Such therapy may also be applicable to the treatment of other infections and residual or recurrent malignancy after CBT...
  13. pmc Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation
    Miguel Angel Perales
    Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 120:4882-91. 2012
    ..Our results indicate that r-hIL-7 can enhance immune recovery after a T cell-depleted allo-HSCT without causing significant GVHD or other serious toxicity (www.clinicaltrials.gov; NCT00684008)...
  14. pmc WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions
    Eleanor M Tyler
    Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA
    Blood 121:308-17. 2013
    ....
  15. pmc T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies
    Ann A Jakubowski
    Adult Allogeneic Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10065, USA
    Biol Blood Marrow Transplant 17:1335-42. 2011
    ..There was 1 late graft failure. This study demonstrates durable engraftment with a low overall incidence of GVHD. Its curative potential is reflected in the remarkably low relapse rate at 4 years...
  16. pmc Novel strategies for adoptive therapy following HLA disparate transplants
    RICHARD J O'REILLY
    Marrow Transplantation Program, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Best Pract Res Clin Haematol 24:381-91. 2011
    ..These approaches may thus provide new, immediately accessible resources for the generation and broad application of immune cell therapies to treat and prevent severe viral diseases post transplant...
  17. ncbi Allogeneic hematopoietic stem cell transplantation for multiple myeloma: what place, if any?
    Sergio Giralt
    Adult Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
    Curr Hematol Malig Rep 8:284-90. 2013
    ..For an individual patient, the risk benefit ratio of allografting remains uncertain. We review the current data and provide recommendations on where and how allo HSCT for myeloma should be further explored...
  18. ncbi Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy
    Deepa Trivedi
    Allogenic Bone Marrow Transplantation Service, Department of Pediatrics, Transplantation Biology Laboratory, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Blood 105:2793-801. 2005
    ....
  19. ncbi Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation
    RICHARD J O'REILLY
    The Transplantation and Leukemia Service of the Department of Medicine and the Immunology and Molecular Pharmacology Programs at Memorial Sloan Kettering Cancer Center, United States
    Semin Immunol 22:162-72. 2010
    ....
  20. ncbi Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma
    Eleanor M Tyler
    Authors Affiliations Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences Sloan Kettering Institute Department of Pathology, Bone Marrow Transplant Service, Department of Pediatrics, and Adult Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center The Tisch Cancer Institute, Hess Center for Science and Medicine, Icahn School of Medicine at Mount Sinai and Weill Medical College of Cornell University, New York, New YorkAuthors Affiliations Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences Sloan Kettering Institute Department of Pathology, Bone Marrow Transplant Service, Department of Pediatrics, and Adult Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center The Tisch Cancer Institute, Hess Center for Science and Medicine, Icahn School of Medicine at Mount Sinai and Weill Medical College of Cornell University, New York, New York
    Cancer Immunol Res 2:547-58. 2014
    ..Together, these findings support the development of immunotherapeutic strategies that aim to enhance CT7-directed immune responses for the treatment of multiple myeloma...
  21. ncbi Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Leuk Res 29:679-83. 2005
    ..No clinical toxicity was observed. The therapeutic efficacy and lack of toxicity of this combination supports further investigation into its clinical utility...
  22. ncbi Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes
    Guenther Koehne
    Allogeneic Bone Marrow Transplantation Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Nat Biotechnol 21:405-13. 2003
    ..This technique for imaging the migration of ex vivo-transduced antigen-specific T cells in vivo is informative, nontoxic, and potentially applicable to humans...
  23. ncbi A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma
    Nikoletta Lendvai
    Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY Department of Medicine, Weill Medical College of Cornell University, New York, NY and
    Blood 124:899-906. 2014
    ..Seven patients (16%) discontinued treatment due to AEs. Carfilzomib 56 mg/m(2) ± dexamethasone was tolerable and provided durable responses. This trial was registered at www.clinicaltrials.gov as #NCT01351623. ..